Home / World / World Lifestyle / Archive by category Health & Medical

Archive by category Health & Medical

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-’749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

More than 92% of schizophrenia patients taking TEV-‘749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1 New data from UZEDY® (risperidone) evaluated predictors of response in schizophrenia with efficacy observed across patient demographic and clinical characteristics in the Phase 3 RISE trial Teva continues its commitment [...]

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity New facility replaces initial and unutilized USD 1.25 billion RCF, in place since spin-off in 2023 Dual-tranche CHF 400m and single-tranche EUR 500 [...]

OPEN Health Appoints Matt D’Auria as Chief Executive Officer to Drive Innovation and Growth

London, March 31, 2025 (Korea Bizwire) – OPEN Health Group is pleased to announce the appointment of Matt D’Auria as its new Chief Executive Officer (CEO). Based in the US, Matt brings more than 25 years of experience in medical affairs and scientific commercialization to his new role, where he will focus on refining and deploying an [...]

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, March 28, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue of Junshi Biosciences was [...]

Arialief Reviews & Complaints (ALERT): Is This Nerve Pain Breakthrough Too Good To Be Real?

SEATTLE, March 28, 2025 (Korea Bizwire) – Nerve pain is brutal. Whether it’s the persistent tingling, relentless burning, or sharp, electric jabs that come without warning—it can turn everyday life into a constant battle. More than 30,000+ users are now turning to this new supplement that promises to do what pharmaceuticals rarely can: deliver real, long-term relief without [...]

PurDentix Reviews & Complaints (URGENT REPORT): Is This Probiotic Tooth Saver Too Good To Be True?

SEATTLE, March 28, 2025 (Korea Bizwire) – If you’ve been following the exploding buzz in the health world, you’ve likely heard of PurDentix—a so-called “8-second probiotic tooth saver” being hailed as a groundbreaking alternative to mouthwash, flossing, and even routine dentist visits. But with this level of hype, comes the inevitable question: Does PurDentix REALLY work, or [...]

Impulse Dynamics Receives European CE Mark For Expanded Indication For Diastolic Heart Failure

CCM therapy is now indicated for symptomatic heart failure patients with diastolic or systolic ventricular dysfunction, offering a broader range of patients a new option for improving quality of life and reducing heart failure hospitalization Marlton, NJ, March 28, 2025 (Korea Bizwire) – Impulse Dynamics plc, a global medical device company dedicated to improving the [...]

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the [...]

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, 2025 (Korea Bizwire) – Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products [...]

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from [...]